Intracoronary recombinant tissue-type plasminogen activator (rt-PA)

Area of Science:

• Cardiology
• Interventional Cardiology
• Thrombolytic Therapy

Background:

• Intracoronary recombinant tissue plasminogen activator (rt-PA) is utilized for acute myocardial infarction (AMI) post-intravenous thrombolysis failure or when angioplasty is not feasible.
• It is also employed for managing thrombotic complications during and before angioplasty procedures.
• Intracoronary administration allows for high local drug concentrations, potentially enabling lower overall doses.

Purpose of the Study:

• To evaluate the role and efficacy of intracoronary rt-PA in managing acute and non-acute coronary occlusions.
• To identify areas requiring further controlled investigation for optimal application of intracoronary rt-PA.

Main Methods:

• Review of existing clinical applications of intracoronary rt-PA.
• Analysis of potential benefits regarding local concentration and dose reduction.
• Identification of knowledge gaps in patient selection, endpoints, dosing, and comparative efficacy.

Main Results:

• Intracoronary rt-PA has demonstrated utility in specific scenarios of AMI and angioplasty-related thrombosis.
• The localized delivery approach shows promise for enhanced efficacy and potentially reduced systemic effects.

Conclusions:

• Intracoronary rt-PA is a viable option when intracoronary thrombus is present and the administration route is accessible.
• Further controlled studies are essential to refine patient selection, dosing strategies, and compare its efficacy against other thrombolytic agents.